Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 5/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.36 |
| ▸ | CHUK | O15111 | 9/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17036478 | 0.84 | GRM5 (0.47) | GRM5MAP3K14KDM4E | |
| SCHEMBL16256042 | 0.78 | TTBK1 (0.36) | TTBK1CHUKCHRNB2CHRNA3CHRNA2 | |
| SCHEMBL15870932 | 0.76 | GRM5 (0.59) | GRM5KDM4E | |
| SCHEMBL31286309 | 0.76 | GRM5 (0.59) | GRM5KDM4E | |
| SCHEMBL1201922 | 0.73 | GRM5 (0.49) | GRM5 | |
| SCHEMBL15870983 | 0.73 | — | — | |
| SCHEMBL29994137 | 0.73 | — | — | |
| SCHEMBL5545972 | 0.70 | TTBK1 (0.43) | TTBK1MAP3K14CHUKKDM4E | |
| SCHEMBL4637898 | 0.69 | GRM5 (0.49) | GRM5KDM4E | |
| SCHEMBL31398425 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847545-B1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | UBE INDUSTRIES (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8137821-B2 | Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same | UBE INDUSTRIES, LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | UBE INDUSTRIES, LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1847545-A1 | SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | Ube Industries, Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090091243-A1 | Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same | ACSL3, ATXN2L, ACSL1 | GRM5 1297/4885TTBK1 2484/4885MAP3K14 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.